Bio Medica Laboratories IPO
GMP, Subscription, Price, Dates & Financial Details
Pharmaceutical & Drugs
Bio Medica Laboratories is engaged in the manufacturing of pharmaceutical parenteral formulations, offering a diverse portfolio of ethical drugs, generic medicines, and over-the-counter (OTC) products. The company specializes in the production of liquid and dry powder injectables available in both…
Open Date
Thu, 21 May 2026
Close Date
Mon, 25 May 2026
Price Band
₹ 132 – 139
Lot Size
1000
Issue Size
₹ 52.00 Cr
Minimum Investment
₹ 278,000 (2000 Shares)
Grey Market Premium Analysis
Day Wise GMP→Unofficial premium quoted in the grey market, tracked daily against the price band cap.
Grey market trading is unregulated. GMP figures are indicative only and should not be the sole basis for investment decisions - treat as a sentiment indicator, not a guarantee.
IPO Details
Bio Medica Laboratories IPO has successfully completed its IPO process and is now listed on NSE SME Platform. According to the Red Herring Prospectus (RHP), the IPO was a book-built issue with a total issue size of ₹52.00 Crore, comprising a fresh issue of 32.06 Lakh equity shares aggregating to ₹45.00 Crore and an offer for sale (OFS) of 3.77 Lakh equity shares aggregating to ₹5.00 Crore by the existing shareholders.
The Bio Medica Laboratories IPO remained open for subscription from May 21, 2026, to May 25, 2026. The basis of allotment was finalized on May 26, 2026, and the company's shares were listed on NSE SME Platform on May 29, 2026.
The company had fixed the price band at ₹132 to ₹139 per share, with a lot size of 1000 shares. Retail investors were required to make a minimum investment of ₹278,000 (based on the upper price band) to apply for one lot.
Skyline Financial Services Private Ltd served as the registrar to the issue. Narnolia Financial Services acted as the Book Running Lead Managers (BRLMs) to the issue.
With the successful completion of the IPO process, Bio Medica Laboratories Limited is now a publicly listed company on NSE SME Platform. Investors can track the company's share price, trading performance, financial results, and corporate announcements through the stock exchanges.
Bio Medica Laboratories IPO Timeline (Tentative)
- IPO Open Date
- Thu, 21 May 26
- IPO Close Date
- Mon, 25 May 26
- Basis of Allotment
- Tue, 26 May 26
- Initiation of Refunds
- Wed, 27 May 26
- Credit of Shares to Demat
- Wed, 27 May 26
- Listing Date
- Fri, 29 May 26 — NSE & BSE
Open Date
21 May 2026
Close Date
25 May 2026
Basis Of Allotment
26 May 2026
Listing Date
29 May 2026
IPO Subscription
Check Live Subscription →The Bio Medica Laboratories IPO has received bids for 82,77,000 shares against 35,83,000 shares offered, resulting in an overall subscription of 2.31x. the NII category is subscribed 1.41x, Retail Investors 2.92x, and QIBs 15.94x. Within the NII category, BNII is subscribed 1.02x, while SNII is subscribed 2.19x.
QIB
15.94x
NII
1.41x
BNII
1.02x
SNII
2.19x
RII
2.92x
Total
2.31x
IPO Reservations
The Retail Individual Investor (RII) category has the highest allocation with 17,92,000 shares, representing 50.01% of the total issue. Qualified Institutional Buyers (QIBs) are allocated 36,000 shares (1%), while Non-Institutional Investors (NIIs) receive 17,55,000 shares (48.98%).
| Category | Shares Offered | Shares Offered % |
|---|---|---|
| Qualified Institutions | 36,000 | 1% |
| Non-Institutional | 1,755,000 | 48.98% |
| BNII | 1,170,000 | 32.65% |
| SNII | 585,000 | 16.33% |
| Retail Investors | 1,792,000 | 50.01% |
| Total | 3,583,000 | 100% |
Financials Details(₹ in Crores)
| Particular | 30 Nov 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 65.17 | 39.12 | 19.53 | 17.57 |
| Revenue | 28.63 | 38.33 | 15.34 | 16.25 |
| Profit After Tax | 8.66 | 9.79 | 2.5 | 0.33 |
| Net Worth | 17.12 | 14.73 | 4.94 | 2.44 |
| Reserve & Surplus | 7.94 | 5.55 | 4.84 | 2.34 |
| Total Borrowings | 38.17 | 15.01 | 10.49 | 9.61 |
Financials Performance
Performance Indicators
EPS Pre
Earnings per share before the IPO.
P/E Pre
IPO Offer Price ÷ EPS Pre.
EPS Post
Expected earnings per share after the IPO..
P/E (Post Issue)
IPO Offer Price ÷ EPS Post.
Bio Medica Laboratories Limited KPI Information
| Particular | Nov 2025 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| ROE % | 54.41 | 99.59 | 67.74 | 13.92 |
| ROCE % | 23.22 | 48.2 | 29.92 | 10.16 |
| Debt / Equity | 2.23 | 1.02 | 2.12 | 3.94 |
| RoNW % | 54.41 | 99.59 | 67.74 | 13.92 |
| Pat Margin % | 30.35 | 25.64 | 16.39 | 2.06 |
Peers Comparison
| Company | Face Value | PE Ratio | EPS Basic | EPS Diluted | RoNW | Net Assets |
|---|---|---|---|---|---|---|
| Bio Medica Laboratories Ltd | 10 | 0.00 | 10.67 | 10.67 | 99.59 | 16.05 |
| Zenotech Laboratories Ltd | 10 | 0.00 | 0.92 | 0.92 | 6.01 | 15.76 |
| Shukra Pharmaceuticals Ltd | 1 | 47.57 | 0.22 | 0.22 | 15.90 | 1.43 |
About Bio Medica Laboratories Limited
Bio Medica Laboratories is engaged in the manufacturing of pharmaceutical parenteral formulations, offering a diverse portfolio of ethical drugs, generic medicines, and over-the-counter (OTC) products. The company specializes in the production of liquid and dry powder injectables available in both single-dose and multi-dose formats, catering to the requirements of human as well as veterinary healthcare sectors.
Product Portfolio
- Liquid Injectables: 58 products
- Dry Powder Injectables: 15 products
The company provides a comprehensive range of pharmaceutical products, including:
- Generic drugs
- Branded pharmaceuticals
- OTC medications
- Other injectable formulations
Business Model
Bio Medica Laboratories operates primarily on a Business-to-Business (B2B) contract manufacturing model. The company develops and manufactures formulations for various pharmaceutical companies based on their specific requirements, product specifications, and quality standards.
Certifications & Compliance
The company adheres to stringent quality and regulatory standards and has been awarded:
- Good Manufacturing Practices (GMP) Certification
- Good Laboratory Practices (GLP) Certification
These certifications have been issued by the Food & Drugs Administration, Madhya Pradesh.
Manufacturing Facilities
Bio Medica Laboratories operates two manufacturing facilities located in Indore, equipped to support the production of high-quality injectable pharmaceutical formulations.
Bio Medica Laboratories IPO Promoters
- Mukesh Mehta
- Pradeep Mehta
Promoters Holding
Holding Pre Issue
99.99%
Holding Post Issue
0.00%
Bio Medica Laboratories IPO Objective
The Company Bio Medica Laboratories IPO proposes to utilise the Net Proceeds from the Issue towards the following objects.
- Repayment of Loan
- Enhancement of its existing production capabilities by setting up of new manufacturing facility at the existing premises
- General Corporate Purposes
Bio Medica Laboratories Limited Address / Contact Details
Bio Medica Laboratories Ltd.
Plot No. 11B-11C, Sector-E, Sanwer Road
Industrial Area, Industrial Estate (Indore),
Indore, Madhya Pradesh, 452015
Phone: +91 7314102751
Email: companysecretary@biomedica.co.in
Website: http://www.biomedica.co.in/
IPO Snapshot
Bio Medica Laboratories IPO Lot Size
The Bio Medica Laboratories IPO has a lot size of 1,000 shares. Retail investors require a minimum investment of ₹2,78,000 by applying for 2 lot (2,000 shares). The maximum application allowed for the retail category is 2 lots (2,000 shares), requiring an investment of ₹2,78,000.
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 2 | 2,000 | 278,000.00 |
| Retail (Max) | 2 | 2,000 | 278,000.00 |
| S-HNI (Min) | 3 | 3,000 | 417,000.00 |
| S-HNI (Max) | 7 | 7,000 | 973,000.00 |
| B-HNI (Min) | 8 | 8,000 | 1,112,000.00 |
Issue Reservation
- QIB — 1%
- NII — 48.98%
- RII — 50.01%
Book Running Lead Managers
- Narnolia Financial Services
IPO Documents & Links
Explore More IPOs
Currently Open
Coming Up Next
Disclaimer: This data is for informational purposes only and does not constitute investment advice.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
What is the Bio Medica Laboratories IPO?
Bio Medica Laboratories IPO is a Book-building IPO with a total issue size of ₹52 crore. The Bio Medica Laboratories IPO price band is ₹132 to 139 per share. The Bio Medica Laboratories IPO subscription opens on Thu, May 21, 2026, and closes on Mon, May 25, 2026. The Bio Medica Laboratories IPO will be listed on the NSE. Skyline Financial Services Private Ltd is the registrar for the Bio Medica Laboratories IPO.
When will the Bio Medica Laboratories IPO open for subscription?
The Bio Medica Laboratories IPO opens on Thu, May 21, 2026 and closes on Mon, May 25, 2026
What is Bio Medica Laboratories IPO Price Band?
Bio Medica Laboratories IPO Price Band is ₹132 to 139 per share.
What is Bio Medica Laboratories IPO Lot Size?
Bio Medica Laboratories IPO lot size is 1000 shares, Retail investors need a minimum investment of ₹278000 based on the upper price band
What is the minimum investment for Bio Medica Laboratories IPO?
The minimum investment for Bio Medica Laboratories IPO is ₹278000, based on one lot of 1000 shares at the upper price band of ₹139 per share.
How to apply for Bio Medica Laboratories IPO?
Investors can apply for the Bio Medica Laboratories IPO through the ASBA (Application Supported by Blocked Amount) facility offered by their bank or through UPI using a SEBI-registered broker or trading app. Select the desired lot size, enter your bid within the price band, and submit the application before Mon, May 25, 2026. The application amount remains blocked until the Bio Medica Laboratories IPO allotment is finalized.
What is Bio Medica Laboratories IPO Issue Size?
Bio Medica Laboratories IPO issue size is ₹52 crores.
What is the Bio Medica Laboratories IPO Allotment Date?
Bio Medica Laboratories IPO allotment date is Tue, May 26, 2026.
Who is the Bio Medica Laboratories IPO Registrar?
The registrar for Bio Medica Laboratories IPO is Skyline Financial Services Private Ltd. Investors can go to Skyline Financial Services Private Ltd website to check Bio Medica Laboratories IPO allotment status, refund processing, and other IPO-related information.
Who is the Bio Medica Laboratories IPO Lead Manager?
The book-running lead managers (BRLMs) for the Bio Medica Laboratories IPO are Narnolia Financial Services. The lead managers are responsible for managing the IPO process, including issue structuring, regulatory compliance, marketing the public issue, coordinating with investors, and ensuring a smooth listing process. For complete details, investors should refer to the Bio Medica Laboratories IPO Red Herring Prospectus (RHP).